Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UAILStudy of ursodeoxycholic acid after liver transplantation
ChiCTR-TRC-11001574Phase 4Recruiting
- Sponsor
- Guangdong Provincial Department of Science and Technology
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ursodeoxycholic acid in biliary complication of liver transplantation (BC) and Early allograft dysfunction (EAD) (2 arms), sponsored by Guangdong Provincial Department of Science and Technology. Primary endpoints: Rates of adverse events and severe adverse events, Range of total bilirubin, gamma-glutamyl transferase, and alkaline phosphatase decline at 1 month after transplantation and 2 more. Started Oct 2011; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
biliary complication of liver transplantation (BC)Early allograft dysfunction (EAD)
Beyond the preview
Go deeper on ChiCTR-TRC-11001574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001574.